



RotaTeq[®] (rotavirus vaccine, live, oral, pentavalent) – Expanded indication

- On February 23, 2017, the [FDA approved](#) Merck's [RotaTeq \(rotavirus vaccine, live, oral, pentavalent\)](#), to include prevention of rotavirus gastroenteritis in infants and children caused by type G9 when administered as a 3-dose series to infants between the ages of 6 – 32 weeks.
 - Previously, RotaTeq was only approved for types G1, G2, G3, and G4.
 - The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
- The approval of RotaTeq's expanded indication was based on additional analysis conducted to evaluate efficacy in the prevention of rotavirus gastroenteritis. G9P1A-associated gastroenteritis was observed in 0 out of 356 subjects vs. 5 out of 356 subjects in the placebo group (100%, [95% CI: - 9.0, 100.0]).
 - Furthermore, in a post hoc analysis of health care utilization data involving 68,038 infants, cases due to type G9P1A were reduced by 100% with RotaTeq vs. placebo (0 cases vs. 14 cases, [95% CI: 69.6, 100.0]).
- RotaTeq consists of three ready-to-use liquid doses administered orally starting at 6 – 12 weeks of age, with subsequent doses administered at 4 – 10 week intervals. The third dose should not be given after 32 weeks of age.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.